Bright Peak Therapeutics

Bright Peak Therapeutics is a private biotechnology company founded in 2017, with headquarters in Basel/Allschwil, Switzerland, and a presence in San Diego, California.

The company specializes in protein engineering to develop next-generation multifunctional immunotherapies aimed at treating cancer and autoimmune diseases. The core of Bright Peak's technology includes proprietary chemical protein synthesis, conjugation, and Enhanced Design and Combine (EDC) technology. This allows the company to engineer cytokines with optimized biological properties. Bright Peak is focused on creating a portfolio of first-in-class and best-in-class cytokines and multifunctional precision immunotherapies that precisely control immune activity. Their Bright Peak Immunocytokines combine antibody targeting with cytokine payloads for improved efficacy and reduced off-target effects. The company also refers to some of its engineered products as “duokines,” which involve the conjugation of cytokines. Bright Peak's pipeline includes designer immunotherapies and multifunctional PD-1 inhibitors, with a notable lead program being BPT567, a PD1-IL18 immunoconjugate for solid tumors. The company collaborates with partners, including Ajinomoto, to advance its innovative therapies.